

BUY

Last Traded Price (17 May 2023): US\$0.136 (STI : 3,173.84)

Price Target 12-mth: US\$0.24 (76% upside) (Prev US\$0.45)

Analysts


Rachel TAN +65 6682 3713 racheltanlr@dbs.com

Derek TAN +65 6682 3716 derektan@dbs.com

What's New

- Discussions with potential strategic investor, Mirae are still ongoing and expected to be completed by end-2Q23
- Our ideal capital injection scenario of US\$175m or more to bring gearing down to 40% level will defend MUST against future uncertainties
- While dilution of up to 45% expected; price have substantially priced in this scenario
- Maintain BUY; lower TP to US\$0.24 as we peg our target price to 0.8x on our assumed fully diluted NAV

Price Relative



Forecasts and Valuation

FY Dec (US\$m)	2021A	2022A	2023F	2024F
Gross Revenue	185	203	193	190
Net Property Inc	110	113	109	108
Total Return	39.4	(130)	54.7	45.9
Distribution Inc	85.6	87.9	74.6	65.0
EPU (US cts.)	2.23	(7.3)	3.06	2.55
EPU Gth (%)	nm	nm	nm	(17)
DPU (US cts.)	5.33	4.75	3.80	3.29
DPU Gth (%)	(5)	(11)	(20)	(13)
NAV per shr (US cts.)	67.3	57.4	57.5	57.5
PE (X)	6.1	nm	4.4	5.3
Distribution Yield (%)	39.2	34.9	27.9	24.2
P/NAV (x)	0.2	0.2	0.2	0.2
Aggregate Leverage (%)	42.7	48.6	48.8	49.1
ROAE (%)	3.4	(11.7)	5.3	4.5

Distn. Inc Chng (%): (8) (21)
 Consensus DPU (US \$): 4.20 4.10
 Other Broker Recs: B: 6 S: 0 H: 0

Source of all data on this page: Company, DBS Bank, Bloomberg Finance L.P.

Raising capital the right move for all

Investment Thesis:

Riding on "flight to quality" trends in US office market. Manulife US REIT's (MUST) portfolio comprises trophy/class A office buildings located in key cities in the US that are riding on the "flight to quality" trends as US corporates rationalise their office space in the midst of a new flexible working trends emerging post COVID-19.

Earnings declines given higher vacancy assumptions post 1Q23 update. We lower our FY23F-FY24F DPU by 9% to 21% to factor in higher vacancy, higher costs, and higher interest cost in our estimates. We have yet to factor in the potential impact from capital injection in our estimates, pending details. Stock current yields >25% yield which we believe have priced in the dilutive effects of a possible deleveraging exercise, waiting to be announced.

Headwinds largely priced in, we believe markets have priced in a "capital raise" at current levels. We see an optimal target gearing ratio of 40% (from current 49%) for MUST in order to better defend itself against possible asset valuation declines in the future. We estimate that US\$175m of capital is needed, implying a rights issue. While dilutive, it will be the likely way out for the REIT. Based on our estimates, assuming capital raised at 10% discount to current price will still see MUST offering a fully diluted FY23F yield of c.19% (vs 28% currently), but still way above its historical mean. Every 10% discount in the new issue price will mean a further 3% ppt decline in yield.

Maintain BUY; lower TP to US\$0.24 (vs. US\$0.45 previously). We maintain our BUY rating but lower our TP to US\$0.24, pegged to our fair value, pegged to 0.8x fully diluted NAV of 0.31Scts. Our TP assumed a target yield of 11%, which is at -1 standard deviation level of its historical pre-COVID mean.

Key Risks

Slower-than-expected economic recovery and potential recession in the US. This situation would impact businesses, and that may cause a rising risk of vacancy.

Non-renewal of leases. MUST's financials, operations, and capital growth may be adversely affected by bankruptcy, insolvency, or downturns in the businesses of its tenants, which may lead to the non-renewal of their leases.

At A Glance

Issued Capital (m shrs)	1,777
Mkt. Cap (US\$m/US\$m)	242 / 242
Major Shareholders (%)	
Manulife Financial C	5.5
Prudential PLC	4.4
Manufacturers Life R	3.7
Free Float (%)	94.5
3m Avg. Daily Val (US\$m)	0.91
GIC Industry : Real Estate / Equity Real Estate Investment (REITs)	

WHAT'S NEW

Is rights issue a possible win-win for all?

Awaiting news of capital injection from new strategic shareholder.

Following from the recent release of Manulife US REIT's (MUST) 1Q2023 Business Update, the discussions with Mirae are still ongoing (Mirae deal). We understand that due diligence by Mirae on MUST is substantially completed, with both parties currently negotiating the key terms, which we await more clarity.

With 1Q23 gearing at 49.5%, just a tad below the 50% limit, the need and urgency of a capital injection becomes more apparent, though the hike in gearing could be due to some timing difference in the payout of distributions and proceeds from the divestment of the Tanasbourne property to the sponsor, Manulife.

Overall, key highlights from the business update include :

- Mirae intends to subscribe for more than 9.8% of new units to capitalise MUST and reduce gearing
- Manulife (sponsor) intends to retain its 9.1% stake in MUST
- May see gearing reduce to the low 40% level

Is the rumoured US\$150m investment by Mirae enough to solve capital structure pressure faced by MUST?

While yet to be confirmed by the manager, assuming that earlier media reports of Mirae intending to acquire a stake in MUST and the REIT manager for US\$150m/c.S\$200m were true, we estimate that a likely scenario of how the capital could be split as follows:

- A US\$109m capital injection by Mirae into MUST (c.32% stake of the enlarged entity) while the remaining US\$41m would be used to acquire the REIT manager (ballpark estimate of c.6x PE)
- MUST would undertake a new issuance of shares valued at c.US\$11m (or a c.3.2% stake of the enlarged entity) (to Manulife Sponsor) to retain its stake of 9.1% in the enlarged entity
- With the estimated US\$41m in proceeds from the sale of the REIT manager, Manulife (sponsor) will likely channel the proceeds to fund the acquisition of Tanasbourne and an additional placement to retain its stake in MUST

In such a scenario above,

- Gearing would be reduced to 42.8%
- ICR ratio will increase to 3.4x
- If the new issuance is priced at a 10% discount to the current share price, we estimate that DPU dilution would be 39% or 42%, assuming a further 5% discount to distributions.

However, we believe that the capital structure remains at a level which could still cause investors' concerns that gearing may be

stretched if capital values continue to fall again by end 2023. This may turn out to be true, depending on how the current turmoil pans out with the US commercial real estate space.

MUST may need to raise further capital to bring gearing to a more comfortable level of less than 40%.

Additional capital of US\$55m to bring gearing to 40%, a level that brings much flexibility to the REIT. While the above is sufficient to bring gearing to a level which is below both the MAS gearing level of 50% and 45% (if ICR is below that of 2.5x), we believe a gearing of above 40% is still not a comfortable level for investors, in view of the potential valuation decline considering the challenging US office market.

As such, we take a step further to evaluate if a rights issue should be considered to bring the gearing a notch lower to ensure a sufficient buffer. In addition, this could be an opportunity and equity solution for existing shareholders who could look to average down on their stake, given the significant decline in the share price.

A possible one-for-six rights issue? Based on our calculation above, a rights issue of US\$55m (to bring the total capital injection up to US\$175m) could be executed via a one-for-six rights issue. Any additional amount from the rights issue, i.e., above US\$55m, would bring gearing down to a more comfortable level of below 40% with ample buffer for a potential asset valuation decline, which we believe would be a win-win scenario to all parties – the sponsor, new sponsor, and unitholders.

Ample defence against the risk of further asset devaluation. With new equity capital raised to bring gearing to a more palatable gearing level of 40%, we believe this will provide MUST with sufficient flexibility to defend against further asset declines in the future, which will need an assumed further 20% decline in asset values to bring gearing back up to 50% level. This implies that MUST balance sheet can withstand a possible "through-cycle" asset devaluation of 32% or a further 120 basis points expansion in cap rates from FY22 levels.

Our scenario analysis with capital injection.

Capital injection a key catalyst for the stock. As the potential strategic injection by Mirae into Manulife US REIT (Mirae deal) remains the key datapoint for most investors and a further clarity will be needed to stem the fall in share price for MUST. Overall, we

Manulife US Real Estate Inv

estimate and calculate the potential scenarios and impact to the share price, DPU, and gearing (table below).

In our scenario analysis, we estimate;

- **An overall US\$175m capital injection** would be needed to bring gearing to 40% with the repayment of debt (to be issued to strategic shareholders and current unitholders)
- Depending on the share price of the new issuance, **DPU dilution (from FY22) is estimated to be 42% to 47%**
- **The impact to the share price is more muted** with a -4% to +4% impact
- In addition, assuming a **further 5% decline in distributable income (DI)**, we estimate that **DPU dilution would be 45% to 49%**
- At a share price of S\$0.14, the stock's fully diluted dividend yield could be around c.19%, levels that are still above historical trading levels.

Maintain BUY; lower TP to US\$0.24. We maintain our BUY rating but lower our TP to US\$0.24, pegged our fair value for MUST post the possible capital injection, which implies a target P/B of 0.8x and a target fully diluted yield of 11%, based on our estimates.

That said, our estimates have not fully reflect this scenario but drop our FY23F-FY24F DPU by c.9% and 21%, respectively, to factor in higher vacancy, higher cost, and higher interest cost (to 4.3% and 5% from 4% and 4.5% previously for FY23F and FY24F, respectively). We have yet to factor in any potential capital injection until further details are revealed.

We believe we are closer to MUST's potential, and able to recap its balance sheet and provide a better platform to weather potential headwinds. As such, all eyes are on the announcement of the potential Mirae deal.

Scenario analysis of potential capital injection (from price of US\$14 scts/unit)

US\$m	FY22	Divest Tanasbourne (Est)	Post Divestment	Assumed Capital Injection of US\$175m	Key metrics Post Capital Injection	
					New units Issued at 10% discount	New Units Issued at 10% premium
Total Debt	1,029	-33.5	995	-175	820	820
Assets	2,079	-33.5	2,045		2,045	2,045
EBITDA	105	- 2.0	103		103	103
Interest Expense	34	-0.4	34	-5.3	28	28
Distributable Income (91% payout)	76		75	5.3	80	80
no. of shares	1,777		1,777	1,389	3,165	2,913
Gearing (from 1Q23) (%)	49.5%		48.7%		40.1%	40.1%
ICR (x)	3.1		3.1		3.6	3.6
DPU (US cts)	4.75		4.23		2.54	2.76
DPU Dilution			-11%		-47%	-35%
Share price (US\$)	0.14		0.14		0.13	0.15
Fully diluted Yield (%)	34%		30%		19%	19%
NAV per share (US\$)	0.55		0.55		0.31	0.34
DBS TP	0.33		0.33		0.24	0.25
P/B at target	0.6x		0.6x		0.8x	0.8x
Yield at target					11%	11%

Source: Company, DBS Bank

Scenario analysis of potential capital injection depending on share price of new issuance


Scenarios	Stable DPU from FY22		5% further decline in DPU	
	DPU (UScts)	Share Price (US\$)	DPU (UScts)	Share Price (US\$)
10% discount	2.54	0.13	2.41	0.13
Current Price	2.66	0.14	2.52	0.14
10% premium	2.76	0.15	2.61	0.15
Dilution from FY22	4.75	0.14	4.75	0.14
10% discount	-47%	-4%	-49%	-4%
Current Price	-44%	0%	-47%	0%
10% premium	-42%	4%	-45%	4%

Source: Company, DBS Bank

Company Background

Manulife US REIT (MUST) is the first pure-play US office REIT listed in Asia. Its portfolio consists of eight freehold, class A, or trophy-quality office properties in Atlanta, Los Angeles, New Jersey, Washington DC, Virginia, and Orange County.

Historical PE and PB band



Source: Bloomberg Finance L.P., DBS Bank estimates



Source: Bloomberg Finance L.P., DBS Bank estimates

Manulife US Real Estate Inv

Income Statement (US\$m)

FY Dec	2020A	2021A	2022A	2023F	2024F
Gross revenue	194	185	203	193	190
Property expenses	(78.5)	(75.6)	(89.4)	(83.4)	(82.3)
Net Property Income	116	110	113	109	108
Other Operating expenses	(11.8)	(11.3)	(11.5)	(8.8)	(7.8)
Other Non Opg (Exp)/Inc	0.0	0.0	48.0	0.0	0.0
Associates & JV Inc	0.0	0.0	0.0	0.0	0.0
Net Interest (Exp)/Inc	(29.6)	(29.1)	(33.9)	(45.4)	(53.4)
Exceptional Gain/(Loss)	(140)	(28.5)	(264)	0.0	0.0
Net Income	(66.0)	40.6	(148)	55.2	46.3
Tax	22.7	(1.1)	18.1	(0.6)	(0.5)
Minority Interest	0.0	0.0	0.0	0.0	0.0
Preference Dividend	0.0	0.0	0.0	0.0	0.0
Net Income After Tax	(43.3)	39.4	(130)	54.7	45.9
Total Return	(43.3)	39.4	(130)	54.7	45.9
Non-tax deductible Items	132	46.2	218	19.9	19.2
Net Inc available for Dist.	89.0	85.6	87.9	74.6	65.0
Growth & Ratio					
Revenue Gth (%)	9.3	(4.7)	9.4	(4.8)	(1.5)
N Property Inc Gth (%)	4.6	(5.4)	3.3	(3.4)	(1.7)
Net Inc Gth (%)	nm	nm	nm	nm	(16.1)
Dist. Payout Ratio (%)	100.0	100.0	95.7	91.0	91.0
Net Prop Inc Margins (%)	59.6	59.2	55.9	56.7	56.7
Net Income Margins (%)	(22.3)	21.3	(64.0)	28.4	24.2
Dist to revenue (%)	45.8	46.2	43.4	38.7	34.3
Managers & Trustee's fees	6.1	6.1	5.7	4.5	4.1
ROAE (%)	(3.6)	3.4	(11.7)	5.3	4.5
ROA (%)	(2.0)	1.8	(5.9)	2.6	2.1
ROCE (%)	5.3	4.8	5.1	5.1	5.0
Int. Cover (x)	3.5	3.4	3.0	2.2	1.9

Source: Company, DBS Bank

Manulife US Real Estate Inv

Interim Income Statement (US\$m)

FY Dec	2H2020	1H2021	2H2021	1H2022	2H2022
Gross revenue	95.7	90.8	94.3	100	102
Property expenses	(42.0)	(34.7)	(40.8)	(42.8)	(46.6)
Net Property Income	53.7	56.1	53.5	57.6	55.5
Other Operating	(5.2)	(5.7)	(5.6)	(6.2)	(5.3)
Other Non Opg (Exp)/Inc	2.20	4.21	9.69	32.8	15.2
Associates & JV Inc	0.0	0.0	0.0	0.0	0.0
Net Interest (Exp)/Inc	(14.9)	(14.7)	(14.5)	(15.3)	(18.6)
Exceptional Gain/(Loss)	0.0	0.0	0.0	0.0	0.0
Net Income	35.8	39.9	43.1	68.9	46.9
Tax	7.74	4.13	(5.3)	(7.7)	25.8
Minority Interest	0.0	0.0	0.0	0.0	0.0
Net Income after Tax	43.5	44.0	37.8	61.2	72.7
Total Return	(7.7)	6.70	32.7	62.8	(192)
Non-tax deductible Items	(2.5)	(1.0)	9.90	(15.2)	(30.8)
Net Inc available for Dist.	41.0	43.0	42.6	46.0	41.9
Growth & Ratio					
Revenue Gth (%)	(3)	(5)	4	6	2
N Property Inc Gth (%)	(14)	4	(5)	8	(4)
Net Inc Gth (%)	4	1	(14)	62	19
Net Prop Inc Margin (%)	56.1	61.8	56.7	57.4	54.4
Dist. Payout Ratio (%)	100.0	100.0	100.0	100.0	91.0

Balance Sheet (US\$m)

FY Dec	2020A	2021A	2022A	2023F	2024F
Investment Properties	1,993	2,184	1,947	1,965	1,984
Other LT Assets	0.0	5.65	47.7	47.7	47.7
Cash & ST Invts	86.7	78.6	113	113	115
Inventory	0.0	0.0	0.0	0.0	0.0
Debtors	6.93	5.55	5.40	8.25	8.13
Other Current Assets	1.66	1.44	2.93	2.93	2.93
Total Assets	2,088	2,276	2,116	2,136	2,158
ST Debt	234	297	145	145	145
Creditor	18.1	58.8	31.3	29.1	28.7
Other Current Liab	6.88	8.25	8.50	8.50	8.50
LT Debt	619	675	884	900	916
Other LT Liabilities	52.9	49.6	26.8	26.8	26.8
Unit holders' funds	1,158	1,188	1,020	1,027	1,033
Minority Interests	0.0	0.0	0.0	0.0	0.0
Total Funds & Liabilities	2,088	2,276	2,116	2,136	2,158
Non-Cash Wkg. Capital	(16.4)	(60.0)	(31.4)	(26.4)	(26.1)
Net Cash/(Debt)	(766)	(893)	(916)	(932)	(946)
Ratio					
Current Ratio (x)	0.4	0.2	0.7	0.7	0.7
Quick Ratio (x)	0.4	0.2	0.7	0.7	0.7
Aggregate Leverage (%)	40.8	42.7	48.6	48.8	49.1
Z-Score (X)	1.0	1.0	1.0	1.0	NA

Source: Company, DBS Bank

Manulife US Real Estate Inv

Cash Flow Statement (US\$m)

FY Dec	2020A	2021A	2022A	2023F	2024F
Pre-Tax Income	74.4	40.6	(148)	55.2	46.3
Dep. & Amort.	(0.7)	1.93	4.35	0.0	0.0
Tax Paid	(1.9)	(0.1)	(0.1)	(0.6)	(0.5)
Associates & JV Inc/(Loss)	0.0	0.0	0.0	0.0	0.0
Chg in Wkg.Cap.	(36.6)	(20.8)	1.25	(5.0)	(0.3)
Other Operating CF	187	69.1	234	19.9	19.2
Net Operating CF	222	90.6	92.0	69.6	64.7
Net Invt in Properties	(24.2)	(231)	(25.4)	(1.9)	(2.8)
Other Invt (net)	0.0	0.0	0.0	0.0	0.0
Invt in Assoc. & JV	0.0	0.0	0.0	0.0	0.0
Div from Assoc. & JVs	0.0	0.0	0.0	0.0	0.0
Other Investing CF	0.17	0.02	0.05	(16.1)	(15.9)
Net Investing CF	(24.0)	(231)	(25.4)	(18.0)	(18.8)
Distribution Paid	(70.7)	(84.0)	(88.6)	(67.9)	(59.2)
Chg in Gross Debt	38.6	215	56.0	16.1	15.9
New units issued	0.0	0.70	0.25	0.0	0.0
Other Financing CF	0.0	0.0	0.0	0.0	0.0
Net Financing CF	(32.2)	132	(32.4)	(51.8)	(43.3)
Currency Adjustments	0.05	0.0	0.03	0.0	0.0
Chg in Cash	166	(8.1)	34.3	(0.2)	2.68
Operating CFPS (US cts.)	16.4	6.32	5.11	4.18	3.62
Free CFPS (US cts.)	12.5	(8.0)	3.75	3.79	3.44

Source: Company, DBS Bank

Target Price & Ratings 12-mth History



Note: Share price and Target price are adjusted for corporate actions.

S.No.	Date of Report	Closing Price	12-mth Target Price	Rating
1:	26 May 22	0.59	0.70	BUY
2:	03 Nov 22	0.36	0.48	BUY
3:	08 Feb 23	0.33	0.48	BUY
4:	10 Feb 23	0.29	0.45	BUY

Source: DBS Bank

Analyst: Rachel TAN

Derek TAN

DBS Bank recommendations are based on an Absolute Total Return* Rating system, defined as follows:

STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame)

BUY (>15% total return over the next 12 months for small caps, >10% for large caps)

HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps)

FULLY VALUED (negative total return, i.e., > -10% over the next 12 months)

SELL (negative total return of > -20% over the next 3 months, with identifiable share price catalysts within this time frame)

*Share price appreciation + dividends

Completed Date: 18 May 2023 06:45:03 (SGT)

Dissemination Date: 18 May 2023 06:59:08 (SGT)

Sources for all charts and tables are DBS Bank unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER

This report is prepared by DBS Bank Ltd. This report is solely intended for the clients of DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies.

Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report.

This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that:

- (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of DBS Group's compensation to any specific investment banking function of the DBS Group.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES

1. DBS Bank Ltd, DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), DBSVUSA, or their subsidiaries and/or other affiliates have a proprietary position in Manulife US Real Estate Inv recommended in this report as of 30 Apr 2023.
2. DBS Bank Ltd, DBS HK, DBSVS, DBSVUSA, or their subsidiaries and/or other affiliates have a net long position exceeding 0.5% of the total issued share capital in Manulife US Real Estate Inv recommended in this report as of 30 Apr 2023.
3. DBS Bank Ltd, DBS HK, DBSVS, DBSVUSA, or their subsidiaries and/or other affiliates beneficially own a total of 1% or more of any class of common equity securities of Manulife US Real Estate Inv as of 30 Apr 2023.

Compensation for investment banking services:

4. DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.


Disclosure of previous investment recommendation produced:

5. DBS Bank Ltd, DBS HK, DBSVS, DBSVUSA, their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed on page 1 of this report to view previous investment recommendations published by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	<p>This report is being distributed in Australia by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS") or DBSV HK. DBS Bank Ltd holds Australian Financial Services Licence no. 475946.</p> <p>DBS Bank Ltd, DBSVS and DBSV HK are exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 ("CA") in respect of financial services provided to the recipients. Both DBS and DBSVS are regulated by the Monetary Authority of Singapore under the laws of Singapore, and DBSV HK is regulated by the Hong Kong Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws.</p> <p>Distribution of this report is intended only for "wholesale investors" within the meaning of the CA.</p>
Hong Kong	<p>This report has been prepared by a personnel of DBS Bank Ltd, who is not licensed by the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities in Hong Kong pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). This report is being distributed in Hong Kong and is attributable to DBS Bank (Hong Kong) Limited ("DBS HK"), a registered institution registered with the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). DBS Bank Ltd., Hong Kong Branch is a limited liability company incorporated in Singapore.</p> <p>For any query regarding the materials herein, please contact Dennis Lam (Reg No. AH8290) at dbsvhk@dbs.com</p>
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	<p>This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBSR"). Recipients of this report, received from ADBSR are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBSR (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services from the subject companies.</p> <p style="text-align: right;">  Wong Ming Tek, Executive Director, ADBSR </p>
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6878 8888 for matters arising from, or in connection with the report.
Thailand	<p>This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.</p> <p>For any query regarding the materials herein, please contact Chanpen Sirithanarattanukul at research@th.dbs.com</p>

Manulife US Real Estate Inv

<p>United Kingdom</p>	<p>This report is produced by DBS Bank Ltd which is regulated by the Monetary Authority of Singapore.</p> <p>This report is disseminated in the United Kingdom by DBS Bank Ltd, London Branch ("DBS UK"). DBS UK is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request.</p> <p>In respect of the United Kingdom, this report is solely intended for the clients of DBS UK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS UK, This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.</p>
<p>Dubai International Financial Centre</p>	<p>This communication is provided to you as a Professional Client or Market Counterparty as defined in the DFSA Rulebook Conduct of Business Module (the "COB Module"), and should not be relied upon or acted on by any person which does not meet the criteria to be classified as a Professional Client or Market Counterparty under the DFSA rules.</p> <p>This communication is from the branch of DBS Bank Ltd operating in the Dubai International Financial Centre (the "DIFC") under the trading name "DBS Bank Ltd. (DIFC Branch)" ("DBS DIFC"), registered with the DIFC Registrar of Companies under number 156 and having its registered office at units 608 - 610, 6th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates.</p> <p>DBS DIFC is regulated by the Dubai Financial Services Authority (the "DFSA") with a DFSA reference number F000164. For more information on DBS DIFC and its affiliates, please see http://www.dbs.com/ae/our-network/default.page.</p> <p>Where this communication contains a research report, this research report is prepared by the entity referred to therein, which may be DBS Bank Ltd or a third party, and is provided to you by DBS DIFC. The research report has not been reviewed or authorised by the DFSA. Such research report is distributed on the express understanding that, whilst the information contained within is believed to be reliable, the information has not been independently verified by DBS DIFC.</p> <p>Unless otherwise indicated, this communication does not constitute an "Offer of Securities to the Public" as defined under Article 12 of the Markets Law (DIFC Law No.1 of 2012) or an "Offer of a Unit of a Fund" as defined under Article 19(2) of the Collective Investment Law (DIFC Law No.2 of 2010).</p> <p>The DFSA has no responsibility for reviewing or verifying this communication or any associated documents in connection with this investment and it is not subject to any form of regulation or approval by the DFSA. Accordingly, the DFSA has not approved this communication or any other associated documents in connection with this investment nor taken any steps to verify the information set out in this communication or any associated documents, and has no responsibility for them. The DFSA has not assessed the suitability of any investments to which the communication relates and, in respect of any Islamic investments (or other investments identified to be Shari'a compliant), neither we nor the DFSA has determined whether they are Shari'a compliant in any way.</p> <p>Any investments which this communication relates to may be illiquid and/or subject to restrictions on their resale. Prospective purchasers should conduct their own due diligence on any investments. If you do not understand the contents of this document you should consult an authorised financial adviser.</p>

Manulife US Real Estate Inv

United States	This report was prepared by DBS Bank Ltd. DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

DBS Regional Research Offices

HONG KONG

DBS (Hong Kong) Ltd

Contact: Dennis Lam
13th Floor One Island East,
18 Westlands Road,
Quarry Bay, Hong Kong
Tel: 852 3668 4181
Fax: 852 2521 1812
e-mail: dbsvhk@dbs.com

SINGAPORE

DBS Bank Ltd

Contact: Paul Yong
12 Marina Boulevard,
Marina Bay Financial Centre Tower 3
Singapore 018982
Tel: 65 6878 8888
e-mail: groupresearch@dbs.com
Company Regn. No. 196800306E

INDONESIA

PT DBS Vickers Sekuritas (Indonesia)

Contact: Maynard Priajaya Arif
DBS Bank Tower
Ciputra World 1, 32/F
Jl. Prof. Dr. Satrio Kav. 3-5
Jakarta 12940, Indonesia
Tel: 62 21 3003 4900
Fax: 6221 3003 4943
e-mail: indonesiaresearch@dbs.com

THAILAND

DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul
989 Siam Piwat Tower Building,
9th, 14th-15th Floor
Rama 1 Road, Pathumwan,
Bangkok Thailand 10330
Tel. 66 2 857 7831
Fax: 66 2 658 1269
e-mail: research@th.dbs.com
Company Regn. No 0105539127012
Securities and Exchange Commission, Thailand